🔥 The Firm Behind the World's Go-To TB Blood Test Just Agreed to a €10.8 Billion Cash Buyout

If you have ever had a tuberculosis blood test, there is a good chance a Qiagen machine ran it. Now the company that makes that test is about to disappear from the stock market.

On October 22, 2026, Swedish buyout giant EQT agreed to take Qiagen private for about €10.8 billion — roughly $12.1 billion — in an all-cash deal (mddionline). That enterprise value includes around $1.1 billion of net debt, and it hands shareholders €46.50 a share to walk away (GEN).

Qiagen isn’t a household name, but its kit sits in labs almost everywhere: it serves more than 500,000 customers and runs the sample-prep, PCR and molecular-diagnostics steps behind everything from cancer panels to its flagship QuantiFERON TB test (pulse2).

The thesis: one of the quiet workhorses of modern diagnostics is being pulled off the public market by private equity and two of the world’s largest state-backed funds — and the price tells you exactly how much that plumbing is worth.

🧠 Why This Matters

Diagnostics is the unglamorous half of healthcare. Nobody tweets about the reagent that isolates DNA from your blood sample. But that plumbing is sticky, recurring revenue — labs buy the same consumables year after year — and that is precisely the kind of cash flow private equity loves to own away from the quarterly-earnings spotlight.

Qiagen’s numbers show why. Its preliminary third-quarter 2026 results logged $548 million in net sales and $0.65 of adjusted diluted earnings per share (mddionline). Annualize that and you get a business clearing north of $2 billion a year in sales — steady, profitable, and spread across roughly 5,400 employees in more than 35 locations (pulse2).

“This is the best path forward for Qiagen, its shareholders, and other stakeholders.” — Stephen H. Rusckowski, Chairman of Qiagen’s Supervisory Board (GEN)

When a board calls a buyout the best path forward, read it plainly: the public market wasn’t giving the company the valuation its owners thought it deserved.

📊 Deep Dive

The headline number is €10.8 billion. The more interesting story is in the premium — because there are three different ones depending on where you start counting:

• Deal value: ~€10.8 billion enterprise value, about $12.1 billion, all cash — including ~$1.1 billion of net debt (GEN).
• Offer price: €46.50 per share, equivalent to about $51.88 (GEN).
• Premium vs. recent price: just 8.6% over the close the day before the deal (GEN).
• Premium vs. pre-rumor price: 40.3% over the €33.15 close on July 8 — the last trading day before private-equity interest leaked (mddionline).
• Premium vs. three-month average: nearly 47% over the volume-weighted average price through that July date (mddionline).

That gap is the whole game. By the time the ink dried, Qiagen’s stock had already run up on takeover chatter, so the announced premium looks thin. Measure from before anyone knew a deal was coming, and buyers are paying 40% over the undisturbed price. The market, in other words, spent three months pricing in the rumor.

EQT isn’t writing the check alone. The firm — which manages roughly €354 billion in assets — is bringing in two heavyweight co-investors: Luxinva, a subsidiary of the Abu Dhabi Investment Authority (ADIA), and CPP Investment Board Europe, part of Canada Pension Plan Investments (GEN). The deal runs through a holding vehicle with the delightfully bland name Crown NL Bidco (mddionline).

⚠️ The Catch

A signed agreement is not a closed deal. This one isn’t expected to complete until mid-2027 (mddionline), which leaves the better part of a year for shareholder votes, regulators across multiple jurisdictions, and the usual tender-offer mechanics.

The thin 8.6% headline premium is also a soft spot. Some investors who bought in on the rumor may feel the final offer leaves money on the table, and take-private deals at modest premiums sometimes draw grumbling — or a sweetened bid — before they clear. And a diagnostics company whose kit touches patient samples in dozens of countries is exactly the kind of cross-border healthcare asset antitrust reviewers like to pick over.

“EQT brings deep sector experience, a global network and operational capabilities.” — Matteo Thun-Hohenstein, Partner at EQT (GEN)

Translation: EQT plans to run this thing harder away from public scrutiny. Whether that means more investment in the pipeline or tighter cost discipline is the open question for Qiagen’s 5,400 employees.

🎯 What Happens Next

Qiagen keeps its name after the deal closes (mddionline), so your lab’s reagent boxes will look the same. Behind the label, expect EQT to do what buyout firms do: push into higher-margin molecular diagnostics, lean on that half-million-customer base, and set up for an eventual re-listing or sale a few years out at a bigger number.

Watch three things between now and mid-2027: whether any shareholder group pushes back on the price, whether regulators in Europe and the US add conditions, and whether a rival bidder decides €46.50 undervalues a near-irreplaceable piece of the diagnostics supply chain.

🧩 Bigger Picture

This is part of a broader move: patient money is buying the boring, essential layers of healthcare. Pairing a buyout firm with sovereign and pension capital — ADIA and CPP here — is how the biggest take-privates get financed now, because the checks are enormous and the investors want decades, not quarters.

Diagnostics tools are a near-perfect fit for that model. The equipment is embedded in lab workflows, switching costs are high, and demand grows with every new test added to the menu. You don’t need a blockbuster drug to make it pay. You just need to own the plumbing — and be patient.

Qiagen spent years as a mid-cap that investors never quite knew how to value. EQT just answered the question with €10.8 billion in cash: the plumbing is worth a fortune, you simply have to take it private to prove it.

---

Sources

• EQT to Take Qiagen Private in €10.8 Billion Takeover — MD+DI
• EQT to Acquire Qiagen for $12.1B, Plans to Take Tools, Diagnostics Provider Private — GEN
• EQT to Acquire QIAGEN in €10.8 Billion Take-Private With ADIA and CPP Investments — Pulse 2.0
• Qiagen agrees to go private with €10.8B takeover by EQT — European Biotechnology

❓ Quick answers

How much is EQT paying for Qiagen?

About €10.8 billion (roughly $12.1 billion) in enterprise value, all cash, at €46.50 per share, announced October 22, 2026 (mddionline, GEN).

Who is buying Qiagen?

Swedish buyout firm EQT, which manages about €354 billion, alongside co-investors Luxinva (Abu Dhabi Investment Authority) and CPP Investment Board Europe (Canada Pension Plan Investments) (GEN, pulse2).

When will the Qiagen deal close?

The take-private is expected to complete around mid-2027, pending shareholder approval and regulatory clearances (mddionline).